Raptor Pharmaceutical Inc. (RPTP) Obtains Tissue Fibrotic Disease Intellectual Property Related to Cysteamine  
10/10/2012 9:53:23 AM

NOVATO, Calif., Oct. 10, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that the Company has acquired exclusive world-wide rights to intellectual property related to cysteamine and related compounds in the potential treatment of tissue fibrosis from the Seattle Children's Research Institute ("SCRI").